Showing results (31-40 of 435) with videos related to
Sort By:
Pageof 44
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.Clinical Lymphoma & Myeloma|June 27, 2006
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myelomaBart Barlogie, Maurizio Zangari, Vanessa Bolejack, et al.Ultrastructural Pathology|February 27, 2008
Morphologic heterogeneity of renal light-chain deposition diseaseNeriman Gokden, Bart Barlogie, Helen LiapisCancer|April 25, 2008
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designsBart Barlogie, Jeff Haessler, Mauricio Pineda-Roman, et al.Seminars in Hematology|October 29, 2003
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profilingFenghuang Zhan, Bart Barlogie, John ShaughnessyCancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.British Journal of Haematology|July 25, 2003
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplantsJoth Jacobson, Bart Barlogie, John Shaughnessy, et al.Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.Cancer|May 13, 2008
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie, Elias Anaissie, Jeffrey Haessler, et al.Blood|June 5, 2014
The future of autologous stem cell transplantation in myelomaFrits van Rhee, Sergio Giralt, Bart BarlogiePageof 44